Encouraging trends in modern phase 1 oncology trials

New England Journal of Medicine

Volumn 378, Issue 23, 2018, Pages 2342-2343

  Chakiba, Camille ^a   Grellety, Thomas ^a   Bellera, Carine ^a   Italiano, Antoine ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC MONOCLONAL ANTIBODY; PEMBROLIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER RESEARCH; DRUG INDUSTRY; DRUG RESPONSE; HUMAN; LETTER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TUMOR CLASSIFICATION; FINANCIAL MANAGEMENT; NEOPLASM; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; NEOPLASMS; RESEARCH SUPPORT AS TOPIC; TREATMENT OUTCOME;

EID: 85048323992     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1803837     Document Type: Letter

References (4)

1. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol 1990; 1: 175-81.
2. Von Hoff DD, Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 1991; 9: 115-22.
3. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
4. Kang SP, Gergich K, Lubiniecki GM, et al. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Ann Oncol 2017; 28: 1388-98.